Hong Kong stock anomaly | BeiGene (06160.HK) rises more than 5% to showcase the latest results of the SEQUOIA study of zebutinib (bizebulinib) at the ASCO 2025 annual meeting.

According to the Securities Times app, BeiGene (06160.HK) rose by over 5%, as of the time of publication, it increased by 4.89% to 158.6 Hong Kong dollars, with a turnover of 5.08 billion Hong Kong dollars.